CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Tocilizumab

Tocilizumab

Last Updated: February 23, 2015

Result type: Reports

Project Number: SR0374-000

Product Line: Reimbursement Review

Generic Name: Tocilizumab

Brand Name: Actemra

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Arthritis, rheumatoid

Indications: Arthritis, Rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 19, 2015

Recommendation Type: List with criteria/condition

Tocilizumab

Files